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Introduction {#sec001}
============

Liquid biopsy using circulating tumor DNA (ctDNA) isolated from peripheral blood has been clinically applied in cancer treatment, including molecular targeted therapy, and its use has spread worldwide \[[@pone.0235611.ref001]\]. In patients with non-small cell lung cancer (NSCLC) bearing epithelial growth factor receptor (*EGFR*) activating/sensitive mutations, such as L858R and exon 19 deletions, *EGFR* tyrosine kinase inhibitors (EGFR-TKIs) have been highly effective in approximately 70% of cases \[[@pone.0235611.ref002],[@pone.0235611.ref003]\]. Detection of *EGFR* mutations with ctDNA in NSCLC has been approved as a companion diagnostic for EGFR-TKIs. As technologies of molecular biology have rapidly progressed, sensitivity of mutation detection has improved to 0.03% with the next generation sequencing (NGS) technique \[[@pone.0235611.ref004]--[@pone.0235611.ref006]\]. However, whether liquid biopsy is useful in early stages of cancer has not been clarified, since the amount of ctDNA is associated with tumor burden. Achieving further progress at detection requires improved isolation system of ctDNA. It is therefore important to examine mechanisms of how ctDNA is released from tumors and how to effectively isolate it.

Circulating free DNA (cfDNA) exists in peripheral blood and is derived from tumor cells and from normal cells (mainly lymphocytes). Recently, we reported that cfDNA was better isolated with cellulose magnetic beads for DNA capturing, and the amount of ctDNA was greater than that obtained with silica membrane spin columns \[[@pone.0235611.ref007]\]. Using the capillary electrophoresis system, we also demonstrated the existence of bimodal peaks, comprising long fragment cfDNA of 5Kb and short fragment cfDNA of 170bp. We also have shown that poor pre-analytical procedures---such as inadequate plasma storage---caused the appearance of long fragment cfDNA \[[@pone.0235611.ref007],[@pone.0235611.ref008]\]. However, long fragment cfDNA was still observed even after appropriate pre-analytical procedures, but only in patients with advanced lung cancer, not in patients with early stage lung cancer or healthy volunteers. Therefore, we assumed that long fragment cfDNA could be related to tumor progression, but its origin remains in doubt. Short fragment cfDNA has been thought to be an apoptotic product considering that it is the same size as the nucleosome unit \[[@pone.0235611.ref009]\]. Oncosomes at the size of 1--10 μm among EV have been known to appear in peripheral blood of patients with advanced cancer, and primarily contain long fragment cfDNA \[[@pone.0235611.ref010]\].

The rapid progress of technology for liquid biopsy has led to high sensitivity of ctDNA detection, but it is still limited to advanced cancers. It is now necessary to improve the effectiveness of the ctDNA isolation system to allow detection even among patients who are in the early stages of cancer. Based on our previous results, we hypothesized that long fragment cfDNA observed in patients with advanced lung cancer might be contained in oncosomes, so that purification of ctDNA derived from oncosomes could lead to improved sensitivity for detecting ctDNA. In this paper, we report the results of our investigation into the origin of cfDNA, especially that related with EVs, and discuss how to isolate ctDNA effectively.

Materials and methods {#sec002}
=====================

Cell lines {#sec003}
----------

Human lung cancer cell lines H1975 (ATCC^®^ CRL-5905^TM^), H838 (ATCC^®^ CRL-5844^TM^), and H226B were purchased from American Type Culture Collection (Manassas, VA). H1975 cells, which carry the *EGFR* L858R/T790M mutation, were cultured in RPMI-1640 containing high glucose, L-glutamine, and HEPES (ATCC \#30--2001; American Type Culture Collection, Manassas, VA), supplemented with 10% fetal bovine serum, at 37°C in 5% carbon dioxide. H838 cells, which carry the *EGFR* L858R mutation, were cultured in RPMI-1640 supplemented with 10% fetal bovine serum at 37°C in 5% carbon dioxide. H226B cells, which are a human squamous cell lung cancer cell line and do not carry any *EGFR* mutations, were cultured in RPMI-1640 supplemented with 10% fetal bovine serum at 37°C in 5% carbon dioxide.

Patient selection {#sec004}
-----------------

Peripheral blood specimens were obtained from 92 patients with lung cancer, 18 patients with benign pulmonary disease, and 20 healthy individuals. All patients were examined at a Saga University Hospital, from May 2016 to November 2016; volunteers were recruited from among Saga University Hospital staff. The analysis was retrospective. Pathological stage was determined according to the current 7^th^ edition of the TNM classification. The Clinical Research Ethics Committee of Saga University Hospital approved the study protocol. All participants gave informed consent for blood sample collection, and all testing was done according to the Declaration of Helsinki.

Extraction of DNA {#sec005}
-----------------

Peripheral blood specimens were collected into tubes containing 3.2% sodium citrate (product number VP-CA052K; TERUMO CORPORATION, Tokyo, Japan). Plasma was immediately separated from blood cells by 3,000 rpm (1,710 g) centrifugation at 4°C for 20 min. Plasma was collected and stored at −80°C until assays were performed. DNA was isolated from 1 ml plasma using the Maxwell RSC ccfDNA plasma cartridge^®^ (Product no. AS1480; Promega, Mannheim, Germany) according to the manufacturer's instructions. Each DNA sample extracted by Maxwell RSC was eluted with 60 μl TE buffer. All DNA samples were stored at −20°C until further examination.

Quantification of DNA {#sec006}
---------------------

DNA concentration was quantified with the QuantiFluor^®^ dsDNA system and a Quantus^®^ Fluorometer (Promega, Mannheim, Germany). The QuantiFluor^®^ dsDNA System provides a fluorescent DNA-binding dye that enables sensitive and specific quantitation of small amounts of double-stranded DNA (dsDNA) in solution. The dye shows minimal binding to single-stranded DNA (ssDNA) and RNA, allowing specific quantitation of dsDNA. All experiments were performed three times.

Size distribution analysis of DNA {#sec007}
---------------------------------

The size distribution of DNA was examined with a capillary electrophoresis system. We used the High Sensitivity DNA kit (Agilent Technologies Inc., Santa Clara, CA, Product no. 5067--4626), a microchip, and analyzed it with an Agilent 2100 Bioanalyzer^®^ equipped with Expert 2100 software (Agilent Technologies Inc., Santa Clara, CA) according to the manufacturer's instructions. We defined "short fragment cfDNA" as DNA of size 120\~265 bp and "long fragment cfDNA" as 1000\~9000 bp, as reported previously \[[@pone.0235611.ref007]\]. The concentration and molarity of each specified region were automatically calculated against internal standards by Agilent 2100 Expert software version B.02.08.

Isolation of EVs from conditioned media {#sec008}
---------------------------------------

Conditioned media from cancer cell lines was collected after 24 h incubation in media with exosome-depleted FBS (System Biosciences, Palo Alto, CA, USA). Cells were eliminated by centrifugation at 3,000 rpm (1,710 g) for 20 min. Then the supernatant was centrifuged at 10,000 g for 30 min and we obtained the materials (10K pellet). After that, the supernatant was centrifuged at 100,000 g for 60 min and we obtained those pelleted materials (100K pellet). For this step, we used an Optima L-70 ultracentrifuge (Beckman Coulter Inc, USA) with an SW-40i rotor.

Transmission electron microscope (TEM) {#sec009}
--------------------------------------

### Negative staining {#sec010}

The samples were absorbed to formvar film coated copper grids and stained with 2% phosphotungstic acid solution (pH 7.0) for 60 sec.

### Observation and imaging {#sec011}

The grids were observed with a transmission electron microscope (JEM-1400Plus; JEOL Ltd., Tokyo, Japan) at an acceleration voltage of 100 kV. Digital images (3296×2472 pixels) were taken with a CCD camera (EM-14830RUBY2; JEOL Ltd., Tokyo, Japan).

Western blotting {#sec012}
----------------

The fraction containing EVs was washed with PBS, and lysed with buffer containing Tris-HCl (pH 8.0), 150 mM NaCl, 1% [Triton X-100](https://www.sciencedirect.com/topics/medicine-and-dentistry/triton-x-100), 0.1% [sodium dodecyl sulfate](https://www.sciencedirect.com/topics/medicine-and-dentistry/sodium-dodecyl-sulfate), and 1% [sodium deoxycholate](https://www.sciencedirect.com/topics/medicine-and-dentistry/deoxycholate-sodium) with both [phosphatase](https://www.sciencedirect.com/topics/medicine-and-dentistry/phosphatase) and [protease inhibitors](https://www.sciencedirect.com/topics/medicine-and-dentistry/proteinase-inhibitor). Western blotting was conducted by use of the NuPAGE electrophoresis system (NOVEX, San Diego, CA) according to the manufacturer's instructions. The proteins were fractionated by 10% Bis-Tris gel electrophoresis followed by transfer to nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, NH). After blocking with 5% skim milk, we used the following antibodies for western blotting: mouse monoclonal anti-CD9 antibody (1:1000 dilution; COSMO BIO, Tokyo, Japan), mouse monoclonal anti-CD63 antibody (1:500 dilution; COSMO BIO, Tokyo, Japan), BiP antibody (1:1000 dilution; Cell Signaling \#3177), anti Annexin A1 antibody (1:2000 dilution; abcam, ab214486). The ImmunoStar^®^ LD or ImmunoStar^®^ Zeta was used for detection (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan).

Animal experiment {#sec013}
-----------------

NOD/SCID/JAK3^null^ (NOJ) mice were established as described previously \[[@pone.0235611.ref011]\]. They were housed under pathogen-free conditions in animal facilities at Saga University according to institutional guidelines. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Saga University (Permit Number: 24-037-0) \[[@pone.0235611.ref012]\]. All surgery was performed under 2% of isoflurane anesthesia, and all possible efforts were made to minimize suffering. All research staff were provided with training in animal care or handling.

H1975 cells (1×10^7^) were injected into the dorsal flanks of 24 NOJ mice. Tumor volumes, defined as \[(short axis) ^2^ × (long axis)\]/2, and body weight were measured every 3 days. Mice were evaluated daily for signs of morbidity or tumor growth. When body weight decreased by 10% of original weight, or metastatic manifestations---such as superficial lymph node swelling or ascites---were observed, the animal was euthanized by cervical dislocation and dissected within 24 h. No mice died before meeting criteria for euthanasia. Six mice were sacrificed monthly from one to four months after injection to evaluate metastatic status and size distribution of cfDNA. When we dissected the mice, we examined the lungs, liver, brain, lymph nodes, ascites, and pleural effusion for metastases. Peripheral blood samples from the mice were collected into tubes containing 3.2% sodium citrate. Plasma was immediately separated from blood cells by 3,000 rpm (1,710 g) centrifugation at 4˚C for 20 min. Supernatants were collected and stored at −80˚C until assays could be performed. DNA was isolated from 200 μl of plasma with a QIAamp DNA mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's instruction. The DNA concentration was quantified with the QuantiFluor^®^ dsDNA system and a Quantus^®^ Fluorometer. The size distribution of DNA was examined with a capillary electrophoresis system.

Separation of plasma DNA into short and long fragment cfDNA by centrifugation {#sec014}
-----------------------------------------------------------------------------

One ml of plasma was centrifuged by 10,000 g at 4°C for 30 min and we obtained the pelleted materials (10K pellet) as large EVs. Then the supernatant was centrifuged at 100,000g for 60 min and we obtained those pelleted materials (100K pellet) as small EVs (exosomes) and the supernatant as cell-free plasma. DNA was isolated with a Maxwell RSC ccfDNA plasma cartridge^®^ according to the manufacturer's instructions. The size distribution of DNA was examined with a capillary electrophoresis system.

Detection of *EGFR* L858R mutation {#sec015}
----------------------------------

*EGFR* L858R mutation was detected with a QX200 Droplet Disital PCR (ddPCR) system (Bio-Rad, Hercules, CA, USA). Reaction mixtures of L858R mutation for ddPCR were assembled from supermix for probes (No dUTP) (Bio-Rad, Hercules, CA, USA), PrimePCR ddPCR Mutation Assay:*EGFR* p.L858R, Human (Bio-Rad, Hercules, CA, USA), PrimePCR ddPCR Mutation Assay:*EGFR* WT for p.L858R,Human (Bio-Rad, Hercules, CA, USA), and template DNA. Reaction mixtures were loaded into sample wells and analysis was performed with the Quantasoft Software (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions.

Statistical analysis {#sec016}
--------------------

Statistical analysis was conducted with SPSS version 19 (IBM SPSS Statistics, IBM, Tokyo, Japan) and JMP^®^ analysis (SAS Institute Inc., NC, US). Comparisons among three or four groups were made with the nonparametric Kruskal-Wallis test; P \< 0.05 was considered statistically significant. Comparisons between two groups were made with the nonparametric Mann-Whitney U test; P \< 0.05 was considered statistically significant. If the outcome was statistically significant, multiple pairwise comparisons were made with the Steel-Dwass test. The Hodges-Lehmann method was used to estimate median differences and 95% confidence intervals (CIs) for compariing the two groups. Correlation between two groups was assessed with the non-parametric Spearman correlation coefficient.

Results {#sec017}
=======

Total cfDNA higher in lung cancer with extrathoracic metastases than without {#sec018}
----------------------------------------------------------------------------

Study participants are summarized in [Table 1](#pone.0235611.t001){ref-type="table"}. Median cfDNA concentration in 92 patients with lung cancer, 18 patients with benign pulmonary diseases, and 20 healthy individuals was 10.1, 8.0, and 7.5 ng/ml plasma, respectively ([Fig 1A](#pone.0235611.g001){ref-type="fig"}), and the difference between lung cancer and the others was not statistically significant. It was somewhat higher in pathological stage IV, but again the difference was not statistically significant ([Fig 1B](#pone.0235611.g001){ref-type="fig"}). Since we have reported that the frequency of ctDNA was higher in distant metastasis than in the intrathoracic region on the basis of a prospective observational study \[[@pone.0235611.ref013]\], we compared patients with and without extrathoracic metastases. Among patients with lung cancer the median concentration of total cfDNA in those with extrathoracic metastases was significantly higher than in those without metastasis (15.0 ng/ml plasma vs. 9.1 ng/ml plasma), Hodges-Lehmann estimate 6.1 (95%CI 1.5−11.1) p\<0.01 ([Fig 1C](#pone.0235611.g001){ref-type="fig"}). Since we have recently shown that the size distribution of cfDNA fragments in patients with lung cancer is bimodal with peaks around 170 bp (short) and 5 Kb (long) \[[@pone.0235611.ref007]\], we next analyzed with capillary electrophoresis the amount of cfDNA fragments in each size class among the patients with lung cancer. A representative size distribution is shown in [Fig 2A](#pone.0235611.g002){ref-type="fig"}. The molality of each fragment was measured with an Agilent Bioanalyzer as previously reported \[[@pone.0235611.ref007]\]. The median molarity of long fragment cfDNA in patients with metastatic cancer was almost twice as high as in patients without metastases (20.0 pmol/l vs. 11.1 pmol/l), Hodges-Lehmann estimate 8.3 (95%CI 0.8−15.9; p = 0.031; [Fig 2B](#pone.0235611.g002){ref-type="fig"}), whereas the difference in molarity of short fragment cfDNA between patients with and without metastasis was smaller and not statistically significant (880.5 pmol/l vs. 523.7 pmol/l; [Fig 2C](#pone.0235611.g002){ref-type="fig"}). These results suggest the possibility of an association between the presence of long fragment cfDNA and extrathoracic metastasis.

![cfDNA concentration in patients with lung cancer or benign pulmonary disease and in healthy individuals.\
(A) Comparison of cfDNA concentration among the three participant groups. (B) Comparison of cfDNA concentration by pathological stage of lung cancer. (C) Comparison of cfDNA concentration in patients with lung cancer according to presence or absence of distant metastasis.](pone.0235611.g001){#pone.0235611.g001}

![Size distribution of cfDNA analyzed with Agilent Bioanalyzer among patients with lung cancer.\
(A) Size distribution among 5 selected patients. Size distribution of cfDNA fragments in patients with lung cancer is bimodal with peaks around 170 bp (short) and 5 Kb (long). We defined "short fragment cfDNA" as DNA of size 120\~265 bp and "long fragment cfDNA" as 1000\~9000 bp. The concentration and molarity of each specified region were normalized by lower (35 bp) and upper (10380 bp) marker buffers. (B) Comparison of molarity of long fragment cfDNA according to presence or absence of distant metastasis. (C) Comparison of molarity of short fragment cfDNA according to presence or absence of distant metastasis.](pone.0235611.g002){#pone.0235611.g002}

10.1371/journal.pone.0235611.t001

###### Participant characteristics.

![](pone.0235611.t001){#pone.0235611.t001g}

  Group                                          n = 130                                                                  
  ---------------------------------------------- -------------------------------------------------- --------------------- ----
  **Patients with lung cancer**                  **92**                                                                   
                                                 Adenocarcinoma                                     60                    
                                                 Squamous cell carcinoma                            20                    
                                                 Non-small cell carcinoma not otherwise specified   8                     
                                                 Small cell carcinoma                               4                     
                                                 Stage                                              Ⅰ                     42
                                                                                                    Ⅱ                     11
                                                                                                    Ⅲ                     16
                                                                                                    Ⅳ                     22
                                                                                                    Unknown               1
                                                 Without extrathoracic metastasis                   73                    
                                                 With extrathoracic metastasis                      18                    
                                                 Metastatic status unknown                          1                     
                                                 *EGFR* mutation status (adenocarcinoma)                                  
                                                                                                    Ex19 deletion         8
                                                                                                    L858R                 14
                                                                                                    Negative or unknown   38
  **Patients with benign pulmonary disease\***   **18**                                                                   
  **Healthy individuals**                        **20**                                                                   

\* Bacterial pneumonia: 3, Lung abscess: 1, Nontuberculous mycobacterial disease: 3, Tuberculosis: 2, Aspergillosis: 2, Cryptogenic organizing pneumonia: 1, Chronic eosinophilic pneumonia: 1, Sarcoidosis: 1, Pneumothorax: 1, Others: 3

Long fragment DNA detected in same fraction as EVs in conditioned media of lung cancer cell lines {#sec019}
-------------------------------------------------------------------------------------------------

Next, we hypothesized that EVs might play a role in protecting long fragment cfDNA from enzyme-mediated degradation in the blood. Previous studies have reported that the size distribution of DNA from EVs derived from human plasma is located around 6 Kb \[[@pone.0235611.ref014]\]. EVs have been classified into small EVs (exosomes) and large EVs (oncosomes) according to their sizes, and they have been separated by centrifugation \[[@pone.0235611.ref015]--[@pone.0235611.ref017]\]. In addition, oncosomes have been reported to contain more tumor-derived long fragment DNA than exosomes \[[@pone.0235611.ref010]\]. By the protocol shown in [Fig 3A](#pone.0235611.g003){ref-type="fig"}, we were able to observe EVs with a transmission electron microscope (TEM) in each of the 10K and 100K pellets from conditioned media of lung cancer cell lines. Although 10K pellets contained small and large EVs, 100K pellets contained only small EVs ([Fig 3B](#pone.0235611.g003){ref-type="fig"}). Western blotting analysis of 10K and 100K pellets in lung cancer cell lines was based on CD9 and CD63 as markers of small EVs (exosomes), and BiP and Annexin A1 as markers of large EVs (oncosomes) \[[@pone.0235611.ref010],[@pone.0235611.ref018]\]. The 10K pellets tended to contain fewer exosomes and more large EVs than 100K pellets ([Fig 3C](#pone.0235611.g003){ref-type="fig"}). The DNA size distribution of 10K and 100K pellets in lung cancer cell lines comprised only long fragments ([Fig 3D](#pone.0235611.g003){ref-type="fig"}). These results show that both small and large EVs are associated with long fragment DNA in lung cancer cell lines.

![Association of long fragment DNA with extracellular vesicles (EVs) in lung cancer cell lines.\
(A) Protocol for EV isolation using conditioned media of lung cancer cell lines. (B) Images of 10K and 100K pellets with a transmission electron microscope (TEM). (C) Western blotting analysis of 10K and 100K pellets. 5 μg of EV lysate was applied. We used antibodies to CD9 and CD63 as markers of small EVs (exosomes), and BiP and Annexin A1 as markers of large EVs. (D) DNA size distribution among 10K and 100K pellets.](pone.0235611.g003){#pone.0235611.g003}

Short and long fragment cfDNA also detected in plasma of mice with metastases {#sec020}
-----------------------------------------------------------------------------

Next, we investigated whether long fragment DNA was detected in mice with metastases. We previously established an animal model reflecting human metastatic lung cancers by using NOD/SCID/Jak3^null^ (NOJ) mice, which exhibit deficiencies in NK cell activity, macrophage and dendritic cell function, and complement activation, as well as T and B cell deficiencies \[[@pone.0235611.ref012]\]. H1975 cells (1×10^7^) were injected into the dorsal flanks of 24 NOJ mice. Six mice were sacrificed monthly from one to four months after injection to evaluate metastatic status and size distribution of cfDNA. Among 24 mice, quality of cfDNA was good enough for analysis of size distribution in 20 mice, in which 12 of the mice had metastases and 8 did not. Therefore, we compared size distribution of cfDNA between presence and absence of metastasis. The size distribution of cfDNA from animals without and with metastases is shown in [Fig 4A and 4B](#pone.0235611.g004){ref-type="fig"}. Although the amount of short fragment cfDNA was negligible in plasma of mice without metastases, as measured with capillary electrophoresis ([Fig 4A](#pone.0235611.g004){ref-type="fig"}), both short and long fragment cfDNA were clearly present in plasma of mice with metastases ([Fig 4B](#pone.0235611.g004){ref-type="fig"}). Examination of quantity showed that the median molarity of long fragment cfDNA in animals with metastases was more than twice as high than in animals without metastases (29.9 pmol/l vs. 12.2 pmol/l), Hodges-Lehmann estimate 16.6 (95%CI 2.8−54.6) p = 0.016 ([Fig 4C](#pone.0235611.g004){ref-type="fig"}). Median molarity of short fragment cfDNA in animals with metastases was substantially higher than in animals without metastases (1185.0 pmol/l vs. 103.8 pmol/l), Hodges-Lehmann estimate 819.6 (95%CI 78.5−1184.5) p = 0.020 ([Fig 4D](#pone.0235611.g004){ref-type="fig"}). These results show that cancer cell-derived DNA could be degradated in peripheral blood, since ctDNA was contained in both fragments, which has been previously reported \[[@pone.0235611.ref007]\].

![Size distribution of cfDNA in mice injected with H1975 cells.\
(A) Size distribution of cfDNA in mice without metastases. (B) Size distribution of cfDNA in mice with metastases. (C) Comparison of molarity of long fragment cfDNA in mice according to presence or absence of distant metastases. (D) Comparison of molarity of short fragment cfDNA in mice according to presence or absence of distant metastasis.](pone.0235611.g004){#pone.0235611.g004}

Allele frequency of L858R mutation higher in short fragment cfDNA than in long fragment cfDNA {#sec021}
---------------------------------------------------------------------------------------------

To investigate the origins of long and short fragments of cfDNA in human, we separated plasma of lung cancer patients with L858R mutation by the same centrifugation protocol as conditioned media of lung cancer cell lines ([Fig 5A](#pone.0235611.g005){ref-type="fig"}), and we found long fragment cfDNA was mainly identified in 10K pellet and short fragment was detected in supernatant ([Fig 5B](#pone.0235611.g005){ref-type="fig"}). To compare the amount of short and long fragment tumor-derived DNA in patients with lung cancer, cfDNA in plasma collected from 13 patients whose cancer had L858R mutations was separated into short and long fragments by centrifugation. First, we compared the cfDNA concentration, molarity of short fragment cfDNA, molarity of long fragment cfDNA, and molarity of combined short and long fragment cfDNA among the four sample types: plasma, 10K pellets, 100K pellets, and supernatant ([S1 Fig](#pone.0235611.s001){ref-type="supplementary-material"}). Second, we compared the correlation of L858R copy number detected by droplet digital PCR (ddPCR) with the four measures: cfDNA concentration, molarity of short fragment cfDNA, molarity of long fragment cfDNA, and molarity of combined short and long fragment cfDNA ([Fig 5C--5F](#pone.0235611.g005){ref-type="fig"}). L858R copy number was more strongly correlated with cfDNA concentration, molarity of short fragment cfDNA, and molarity of combined short and long fragment cfDNA than with molarity of long fragment cfDNA alone. In addition, the allele frequency of L858R mutation in cfDNA of supernatant tended to be the highest among all sample types ([Fig 5G](#pone.0235611.g005){ref-type="fig"}). The allele frequency of L858R mutation was pronounced in cfDNA of supernatant but effectively zero in 10K pellets (13.0% vs 0.0%), Hodges-Lehmann estimate 12.3 (95%CI 1.1−21.3) p\<0.01 ([Fig 5G](#pone.0235611.g005){ref-type="fig"}). Therefore, tumor-derived DNA from patients with lung cancer is present in significantly higher amounts in short fragment cfDNA than in long fragment cfDNA.

![Allele frequency of *EGFR* L858R mutation of short and long fragment cfDNA in patients with lung cancer.\
(A) The protocol to isolate short and long fragments of cfDNA in plasma from patients with lung cancer patients. (B) A representative result of the size distribution obtained with Bioanalyzer. The results of plasma, 10K pellet, 100K pellet, and supernatant are shown. (C-F) Correlation of L858R copy number with the four measures: cfDNA concentration, molarity of short fragment cfDNA, molarity of long fragment cfDNA, and molarity of combined short and long fragment cfDNA. (G) Comparison among sample types of the allele frequency of *EGFR* L858R mutation by using droplet digital PCR (ddPCR).](pone.0235611.g005){#pone.0235611.g005}

Discussion {#sec022}
==========

In this paper, we have shown that, in patients with lung cancer, total amount of cfDNA was higher in those who had distant metastasis than in those who did not. In particular, the amount of long fragment cfDNA was significantly higher in those patients. Long fragment cfDNA was present together with EVs in the fraction separated by centrifugation of cell culture media. In human plasma samples, long fragment cfDNA was observed in the same fraction as conditioned media, whereas short fragment cfDNA existed in the supernatant after centrifugation at 100,000 g, in which the amount of ctDNA was two times higher than in plasma isolated by a conventional procedure.

The total amount of cfDNA is known to be correlated with tumor burden, stage, number of metastatic sites, and worse overall survival \[[@pone.0235611.ref019]--[@pone.0235611.ref021]\]. Most papers describe cfDNA at size 160--170 bp, and long fragment cfDNA has been thought to be contamination by genomic DNA. We previously reported a pre-analytical procedure for assessing cfDNA, in which we confirmed that long fragment cfDNA appeared in samples stored under inappropriate conditions \[[@pone.0235611.ref008]\]. However, long fragment cfDNA of 5 Kb was definitely observed in patients with advanced lung cancer even under proper conditions, as described in the present paper and our previous paper \[[@pone.0235611.ref007]\]. In cancer cell culture media, only long fragment cfDNA was observed, but in an animal model using the same cancer cells we found both long and short fragment cfDNA. These results suggest that cancer cell-derived DNA could be degraded in peripheral blood, since ctDNA was contained in both fragments.

Recently, large EVs, named oncosomes, have been reported to contain large size DNA \[[@pone.0235611.ref010]\]. EVs vary in size, and the mechanism of their release also differs between small EVs (exosomes) and large EVs (oncosomes). The former are released through fusion of the multi-vesicular body and the plasma membrane, whereas the latter are released directly from the plasma membrane by blebbing and budding mechanisms \[[@pone.0235611.ref022]\] and contain extra-nuclear large size DNA. Long fragment cfDNA has been reported to exist in oncosomes isolated from patients with metastatic prostate cancer, but not in oncosomes isolated from cancer-free individuals \[[@pone.0235611.ref010]\]. Our results indicate that long fragment cfDNA is detected in the same fraction as EVs---including oncosomes and exsosomes---after centrifugation, and short fragment cfDNA was observed after 100,000 g centrifugation, suggesting that association with EVs helps it avoid degradation. The long fragment cfDNA contained little ctDNA on the basis of on the basis of *EGFR* driver mutation L858R as an indicator of ctDNA. EVs mainly contained miRNA and proteins, which are known to be metastasis-associated factors such as brain-derived neurotrophic factor (BDNF), C-X-C motif chemokine 12 (CXCL12), and osteopontin, and are potent mediators of communication between tumor cells and stroma \[[@pone.0235611.ref023]\]. These mediators may contribute to tumor progression, and long fragment cfDNA exists along with these factors. Whether long fragments have a role in tumor progression should be further investigated.

The possible origin of cfDNA is schematically summarized in [Fig 6](#pone.0235611.g006){ref-type="fig"}. cfDNA, including ctDNA, is released from cancer cells, and is mainly degraded into nucleosome units in peripheral blood. cfDNA co-existing with EVs escapes degradation and remains as long fragment cfDNA, although it is not clarified whether cfDNA is inside or outside of the EVs. We also found that the amount of ctDNA is greater in the fraction after centrifugation at 100,000 g than after the conventional method. Recently, median length cfDNA fragments from patients with cancer has been reported to be around 163 bp by analysis of its fragmentation pattern using whole genome sequencing \[[@pone.0235611.ref024]\]. We could not analyze the precise size of ctDNA contained in cfDNA better than with the conventional procedure, but it could be of smaller size since the fraction was obtained with higher-speed centrifugation.

![The possible origin of cfDNA in cancer patients.\
cfDNA, including ctDNA, is released from cancer cells, and is mainly degraded in peripheral blood. cfDNA co-existing with EVs escapes degradation and remains as long fragment cfDNA, although it is not clarified whether cfDNA is inside or outside of the EVs.](pone.0235611.g006){#pone.0235611.g006}

Although we hypothesized that ctDNA is contained in long fragment cfDNA, our results showed that it predominantly exists in short fragment cfDNA. However, we also found that performing just two rounds of centrifugation apparently leads to more effective isolation of ctDNA. In the next step, we need to confirm the usefulness of the method by using a larger number of clinical samples.

Supporting information {#sec023}
======================

###### Comparison of DNA concentration and molarity.

(A-D) Comparison of the DNA concentration, molarity of short fragment DNA, molarity of long fragment DNA, and molarity of combined short and long fragment DNA among plasma, 10K pellets, 100K pellets, and supernatant.
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Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:
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2\. To comply with PLOS ONE submission requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

3\. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as a description of any inclusion/exclusion criteria that were applied to participant recruitment and a description of how participants and healthy volunteers were recruited.

4\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is a translational study on the origin of cfDNA in lung cancer. Authors utilized both cell-line/animal model and plasma samples from human subjects. The experiments were conducted in high quality and manuscript was written clearly. Authors have reported the long fragment cfDNA to be associated with distant metastasis but not the short fragment cfDNA. This is interesting but I do have a number of queries as followed:

1\. Table 1: 22 patients had stage IV disease while only 18 had distant metastasis. Thus 4 patients with stage IV disease actually didn't have M1 disease. Please note that pleural effusion is considered distant metastasis. Please clarify.

2\. Results, first paragraph (line 265): Subheading is misleading. There is no statistical difference in total cfDNA between patient with lung cancer and benign pulmonary disease/healthy individual. Author must change the subheading.

3\. Figure 1: please provide sample size for each group.

4\. There was difference in both short fragment cfDNA (880 vs 523 pmol/l) and long fragment cfDNA (20 vs 11 pmol/l) between patients with and without metastasis. Only statistically significance was reported to be negative for the short fragment cfDNA subgroup. We will need statistical review on this and certainly authors' statement of "long fragment cfDNA was more clearly associated with distant metastasis than short fragment cfDNA" is NOT strongly supported by the data.

5\. Total of 20 mice were analyzed and 12 with metastasis and 8 without. How did the authors evaluate for metastasis? Did they perform CT scan on the mice or did they just examine all the organs after sacrificing the mice? If for the latter, did they include examination of the CNS?

6\. The statement "Although only short fragment cfDNA was detected in plasma of mice without metastases (Fig 4A), both short and long fragment cfDNA was detected in plasma of mice with metastases (Fig 4B)." is a bit confusing. As per Figure 4C and 4D, both short and long fragment cfDNA were present in mice with and without distant metastasis. Only the quantities were different. Please clarify

7\. Please provide the EGFR mutation status of lung cancer patients in Table 1.

8\. Why would the authors analyse only the EGFR 21 L858R mutation? What is the total sample size? Why ignore the testing of EGFR exon 19 deletion (which is also easily analysed by ddPCR)?

9\. The statement, "Since long fragment was detected in same fraction as that observed in cancer cell lines, long fragment DNA was suggested to be associated with EVs" is speculative. cfDNA from cell line would not be metabolized and excreted by kidney, while cfDNA in human subjects are. In absence of data on metabolization and excretion of long vs short fragment DNA, we cannot make direct analogy with observation in cell lines.

Reviewer \#2: This is an interesting paper about the origin of circulating tumor DNA (ctDNA) in patients with lung cancer.

major Critiques:

1\. The authors should clearly state the primary objective, central hypothesis, and primary outcome variable of this research.

2\. Please shorten this manuscript.

3\. In addition to p-values, the authors should report the 95% confidence intervals (CIs) for all major findings.

4\. The authors defined "short fragment cfDNA" as 126 DNA of size 120\~265 bp and "long fragment cfDNA" as 1000\~9000 bp without any justification. Please justify it.

5\. The discussion of the normalization method was superficial. Please provide a detailed justification of it.

6\. The authors stated that "multiple pairwise comparisons were made"; however, they did not clearly specify the method that they used. In addition, it is unclear which p-values reported in this paper were adjusted for the multiple comparisons.

7\. The authors should report the non-parametric Spearman correlation coefficient instead of Pearson correlation coefficient.

8\. The log files of the statistical analyses (not the results) should be added to the supplemental data. This will help readers understand the detailed statistical analysis procedures.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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29 May 2020

Dear Dr. Chalmers:

I am submitting a revised version of our manuscript entitled, \"Origin of circulating free DNA in patients with lung cancer\".

We have attempted to address all of the points raised by the reviewers. We highlighted corresponding manuscript changes and corrections in red. We also found a few mistakes, which we corrected (also in red). Specific responses follow.

Responses to Reviewer \#1

Q1) Table 1: 22 patients had stage IV disease while only 18 had distant metastasis. Thus 4 patients with stage IV disease actually didn't have M1 disease. Please note that pleural effusion is considered distant metastasis. Please clarify.

A1) As the reviewer points out, the motivation for this is not obvious. We therefore added a sentence, and changed Table 1 and Figure 1C, as follows.

Line 231: Since we have reported that the frequency of ctDNA was higher in distant metastasis than in the intrathoracic region on the basis of a prospective observational study (13), we compared patients with and without extrathoracic metastases. Among patients with lung cancer the median concentration of total cfDNA in those with extrathoracic metastases was significantly.....

Table1

Group n=130

Patients with lung cancer 92

Adenocarcinoma 60

Squamous cell carcinoma 20

Non-small cell carcinoma not otherwise specified 8

Small cell carcinoma 4

Stage Ⅰ 42

Ⅱ 11

Ⅲ 16

Ⅳ 22

Unknown 1

Without extrathoracic metastasis 73

With extrathoracic metastasis 18

Metastatic status unknown 1

EGFR mutation status (adenocarcinoma)

Ex19 deletion 8

L858R 14

Negative or unknown 38

Patients with benign pulmonary disease\* 18

Healthy individuals 20

\* Bacterial pneumonia: 3, Lung abscess: 1, Nontuberculous mycobacterial disease: 3, Tuberculosis: 2, Aspergillosis: 2, Cryptogenic organizing pneumonia: 1, Chronic eosinophilic pneumonia: 1, Sarcoidosis: 1, Pneumothorax: 1, Others: 3

Figure 1C

Q2) Results, first paragraph (line 224): Subheading is misleading. There is no statistical difference in total cfDNA between patient with lung cancer and benign pulmonary disease/healthy individual. Author must change the subheading.

A2) We changed the subheading.

Line 224: Total cfDNA higher in lung cancer with extrathoracic metastases than without

Q3) Figure 1: please provide sample size for each group.

A3) We added the sample size for each group in Figure 1 as below.

Q4) There was difference in both short fragment cfDNA (880 vs 523 pmol/l) and long fragment cfDNA (20 vs 11 pmol/l) between patients with and without metastasis. Only statistically significance was reported to be negative for the short fragment cfDNA subgroup. We will need statistical review on this and certainly authors' statement of "long fragment cfDNA was more clearly associated with distant metastasis than short fragment cfDNA" is NOT strongly supported by the data.

A4) We changed the sentence, and we corrected Figures 2B and C as shown below.

Line 247: These results suggest the possibility of an association between the presence of long fragment cfDNA and extrathoracic metastasis.

Figures 2B and C

Q5) Total of 20 mice were analyzed and 12 with metastasis and 8 without. How did the authors evaluate for metastasis? Did they perform CT scan on the mice or did they just examine all the organs after sacrificing the mice? If for the latter, did they include examination of the CNS?

A5) We did not perform CT scans to evaluate metastasis. Instead, we sacrificed and dissected the mice when either body weight decreased by 10% of original weight or metastatic manifestations (such as superficial lymph node swelling or ascites) were observed, as mentioned in Line 181. We conducted systematic examination for metastases, including in the brain.

Q6) The statement "Although only short fragment cfDNA was detected in plasma of mice without metastases (Fig 4A), both short and long fragment cfDNA was detected in plasma of mice with metastases (Fig 4B)." is a bit confusing. As per Figure 4C and 4D, both short and long fragment cfDNA were present in mice with and without distant metastasis. Only the quantities were different. Please clarify

A6) We changed the sentences as follows to avoid causing confusion.

Line 306: Although the amount of short fragment cfDNA was negligible in plasma of mice without extrathoracic metastases, as measured with capillary electrophoresis (Fig 4A), both short and long fragment cfDNA were clearly present in plasma of mice with metastases (Fig 4B). Examination of quantity showed that ......

Q7) Please provide the EGFR mutation status of lung cancer patients in Table 1.

A7) We added EGFR mutation status in Table 1, as shown above (answer to Q1).

Q8) Why would the authors analyse only the EGFR 21 L858R mutation? What is the total sample size? Why ignore the testing of EGFR exon 19 deletion (which is also easily analysed by ddPCR)?

A8) To investigate the content of ctDNA in each faction, at least 2 ml plasma was required. Among 22 plasma samples with over 2ml remaining, 17 were L858R positive and 5 had exon 19 deletions in tissue specimens. If the amount of ctDNA is small, it is sometimes not detected because of degradation; ddPCR could successfully be performed in 14 of the 22 blood samples. The results comprised 13 L858R mutations and 1 exon 19 deletion. Therefore, we analyzed the L858R positive samples for comparison of quantity in each fraction after centrifugation.

Q9) The statement, "Since long fragment was detected in same fraction as that observed in cancer cell lines, long fragment DNA was suggested to be associated with EVs" is speculative. cfDNA from cell line would not be metabolized and excreted by kidney, while cfDNA in human subjects are. In absence of data on metabolization and excretion of long vs short fragment DNA, we cannot make direct analogy with observation in cell lines.

A9) Ideally, we should show co-existence of long fragment cfDNA and EV in human plasma samples. However, detection of EV in human samples by TEM was difficult because the amount of EV was too small. Therefore, we used conditioned medium of cancer cell lines to show EV in the long fragment fraction by TEM.

As the reviewer suggests, association between long fragment and EV is speculative. Therefore, we deleted from line 330 the sentence, "Since long fragment was detected in same fraction as that observed in cancer cell lines, long fragment DNA was suggested to be associated with EVs.". Also, we changed the title of Figure 6 to " Possible origin of ...", and added the following sentence.

Line 404: The possible origin of cfDNA is schematically summarized in Fig 6.

Responses to Reviewer \#2

Q1) The authors should clearly state the primary objective, central hypothesis, and primary outcome variable of this research.

A1)　We added the following sentences at the ends of the Introduction and Discussion sections to clarify the primary objective, hypothesis, and principal outcome variable of this research.

Line 73: The rapid progress of technology for liquid biopsy has led to high sensitivity of ctDNA detection, but it is still limited to advanced cancers. It is now necessary to improve the effectiveness of the ctDNA isolation system to allow detection even among patients who are in the early stages of cancer. Based on our previous results, we hypothesized that long fragment cfDNA observed in patients with advanced lung cancer might be contained in oncosomes, so that purification of ctDNA derived from oncosomes could lead to improved sensitivity for detecting ctDNA.

Line 415: Although we hypothesized that ctDNA is contained in long fragment cfDNA, our results showed that it predominantly exists in short fragment cfDNA. However, we also found that performing just two rounds of centrifugation apparently leads to more effective isolation of ctDNA. In the next step, we need to confirm the usefulness of the method by using a larger number of clinical samples.

Q2) Please shorten this manuscript.

A2)　We deleted some sentences in the Introduction and Discussion sections to remove redundant parts.

Q3) In addition to p-values, the authors should report the 95% confidence intervals (CIs) for all major findings.

A3)　We used JMP® analysis (SAS Institute Inc., NC, US) to compute 95% confidence intervals (CIs) with the cooperation of Prof. Kawaguchi, a biostatistician in Saga University. The Hodges-Lehmann method was used to estimate median differences and 95% CIs for comparison of cfDNA between absence and presence of extrathoracic metastasis overall (Fig. 1C) and for long or short fragments (Fig. 2B, C, Fig. 4C, D). The Steel-Dwass test was used for analysis of multiple pairwise comparisons of allele frequency of L858R among each fraction (Fig. 5G).

We added the following sentences and added Prof. Kawaguchi as a co-author.

Line 216: If the outcome was statistically significant, multiple pairwise comparisons were made with the Steel-Dwass test. The Hodges-Lehmann method was used to estimate median differences and 95% confidence intervals (CIs) for comparing the two groups.

Line 236: Hodges-Lehmann estimate 6.1 (95%CI 1.5�11.1) p\<0.01 (Fig 1C)

Line 244: Hodges-Lehmann estimate 8.3 (95%CI 0.8�15.9) p=0.031 (Fig 2B),

Line 311: Hodges-Lehmann estimate 16.6 (95%CI 2.8�54.6) p=0.016 (Fig 4C).

Line 314: Hodges-Lehmann estimate 819.6 (95%CI 78.5�1184.5) p=0.020 (Fig 4D).

Line 348: Hodges-Lehmann estimate (95%CI 1.1�21.3) p\<0.01 (Fig 5G).

Fig 4C, D

Fig 5G

Q4) The authors defined "short fragment cfDNA" as DNA of size 120\~265 bp and "long fragment cfDNA" as 1000\~9000 bp without any justification. Please justify it.

A4) Our previous analysis showed that two peaks of cfDNA were consistently observed, in the 120\~265 bp and 1000\~9000 bp ranges (reference No.7). Therefore, we defined "short fragment cfDNA" as DNA of size 120\~265 bp and "long fragment cfDNA" as 1000\~9000 bp.

We changed the following sentence.

Line 130: ..."long fragment cfDNA" as 1000\~9000 bp, as reported previously (7).

Q5) The discussion of the normalization method was superficial. Please provide a detailed justification of it.

A5) According to Agilent's instruction, we changed to the following sentences.

Line 131: The concentration and molarity of each specified region were automatically calculated against internal standards by Agilent 2100 Expert software version B.02.08.

Q6) The authors stated that "multiple pairwise comparisons were made"; however, they did not clearly specify the method that they used. In addition, it is unclear which p-values reported in this paper were adjusted for the multiple comparisons.

A6) If the outcome was statistically significant, multiple pairwise comparisons were made with the Steel-Dwass test to compute 95% CI as mentioned in A3, and we added the following sentence.

Line 216: If the outcome was statistically significant, multiple pairwise comparisons were made with the Steel-Dwass test.

Q7) The authors should report the non-parametric Spearman correlation coefficient instead of Pearson correlation coefficient.

A7) We changed the method of calculating the correlation coefficient, as suggested. We changed Figure 5 C,D,E,F, and added the following sentence.

Line 220: groups was assessed with the non-parametric Spearman correlation coefficient.

Q8) The log files of the statistical analyses (not the results) should be added to the supplemental data. This will help readers understand the detailed statistical analysis procedures.

A8) We added the files of the statistical analyses as a supplemental Table.

Sincerely yours,

Naoko Sueoka-Aragane, MD, PhD

Division of Hematology, Respiratory Medicine and Oncology

Department of Internal Medicine

Faculty of Medicine, Saga University

10.1371/journal.pone.0235611.r003
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Dear Dr. Abe,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Jeffrey Chalmers, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors have responded well to the statistical issues raised in the previous review. There is no further statistical concern about this revised manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No
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Dear Dr. Abe:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff

on behalf of

Dr. Jeffrey Chalmers

Academic Editor
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